Asthma outcome measures
| Autor: | Michael Francis Johnston, Joannie Shen, Ron D. Hays |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Exacerbation medicine.drug_class MEDLINE Quality of life immune system diseases Bronchodilator Outcome Assessment Health Care Health care medicine Humans Pharmacology (medical) Anti-Asthmatic Agents Intensive care medicine Asthma Clinical Trials as Topic business.industry Health Policy Outcome measures General Medicine medicine.disease United States Bronchodilator Agents Respiratory Function Tests respiratory tract diseases Clinical trial National Institutes of Health (U.S.) Practice Guidelines as Topic Quality of Life business |
| Zdroj: | Expert Review of Pharmacoeconomics & Outcomes Research. 11:447-453 |
| ISSN: | 1744-8379 1473-7167 |
| DOI: | 10.1586/erp.11.48 |
| Popis: | Asthma is a common chronic disease with underlying inflammation of the airway. Advances in science have led to increased understanding of the heterogeneous nature of asthma and its complex mechanisms. Traditionally, asthma-practice guidelines have focused on optimizing lung function and the US FDA has required increases in lung function and reduction of exacerbation as primary outcomes in clinical trials of new asthma therapeutics. Improved lung function is a critical indicator of bronchodilator therapy, but the importance of long-term asthma control while maintained on controller medication is increasingly emphasized. The NIH asthma guidelines suggest the use of patient-reported outcomes, including health-related quality-of-life measures, to assess asthma control. Clinical practices and research studies concerning asthma can benefit from harmonizing the major outcome measures so that comparisons across studies can be made. In this article, we review common asthma outcome measures with a focus on recent efforts to harmonize outcomes for therapeutic clinical trials in asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|